Trial Profile

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trimodulin (Primary)
Indications Community-acquired pneumonia; COVID 2019 infections; COVID-19 pneumonia
Focus Registrational; Therapeutic Use
Acronyms TRICOVID
Sponsors Biotest AG; Biotest Pharmaceuticals

09 Jun 2025 Status changed from active, no longer recruiting to discontinued.
19 Feb 2025 Planned End Date changed from 31 Aug 2025 to 31 May 2025.
19 Feb 2025 Planned primary completion date changed from 31 Aug 2025 to 31 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com